These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20511481)

  • 21. Gabapentin enacarbil for treatment of restless legs syndrome in adults.
    Hayes WJ; Lemon MD; Farver DK
    Ann Pharmacother; 2012 Feb; 46(2):229-39. PubMed ID: 22298601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gabapentin enacarbil in restless legs syndrome.
    Merlino G; Serafini A; Lorenzut S; Sommaro M; Gigli GL; Valente M
    Drugs Today (Barc); 2010 Jan; 46(1):3-11. PubMed ID: 20200691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.
    Lal R; Sukbuntherng J; Luo W; Tovera J; Lassauzet ML; Cundy KC
    J Clin Pharmacol; 2013 Jan; 53(1):29-40. PubMed ID: 23400741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome.
    Merlino G; Serafini A; Young JJ; Robiony F; Gigli GL; Valente M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):91-102. PubMed ID: 19127491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 52-week study of gabapentin enacarbil in restless legs syndrome.
    Ellenbogen AL; Thein SG; Winslow DH; Becker PM; Tolson JM; Lassauzet ML; Chen D
    Clin Neuropharmacol; 2011; 34(1):8-16. PubMed ID: 21242741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Chen D; Lal R; Zomorodi K; Atluri H; Ho J; Luo W; Tovera J; Bonzo D; Cundy K
    Clin Ther; 2012 Feb; 34(2):351-362.e3. PubMed ID: 22325733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome.
    Inoue Y; Hirata K; Hoshino Y; Yamaguchi Y
    Sleep Med; 2021 Sep; 85():138-146. PubMed ID: 34329897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gabapentin encarbil (Horizant) for restless leg syndrome.
    Med Lett Drugs Ther; 2011 Sep; 53(1372):70-1. PubMed ID: 21897349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials.
    Canafax DM; Bhanegaonkar A; Bharmal M; Calloway M
    BMC Neurol; 2011 Apr; 11():48. PubMed ID: 21527006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
    Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials.
    Ondo WG; Hermanowicz N; Borreguero DG; Jaros MJ; Kim R; Shang G
    J Clin Mov Disord; 2015; 2():9. PubMed ID: 26788345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis.
    Iftikhar IH; Alghothani L; Trotti LM
    Eur J Neurol; 2017 Dec; 24(12):1446-1456. PubMed ID: 28888061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.
    Kushida CA; Walters AS; Becker P; Thein SG; Perkins AT; Roth T; Canafax D; Barrett RW;
    Sleep; 2009 Feb; 32(2):159-68. PubMed ID: 19238802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
    Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ;
    Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison.
    Chen C; Upward J; Arumugham T; Stier B; Davy M
    Clin Ther; 2015 Feb; 37(2):349-57. PubMed ID: 25467190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome.
    Allen R; Chen C; Soaita A; Wohlberg C; Knapp L; Peterson BT; García-Borreguero D; Miceli J
    Sleep Med; 2010 Jun; 11(6):512-9. PubMed ID: 20466589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.
    Imamura S; Kushida C
    Expert Opin Pharmacother; 2010 Aug; 11(11):1925-32. PubMed ID: 20629607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?
    Kume A
    Neuropsychiatr Dis Treat; 2014; 10():249-62. PubMed ID: 24523590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatment options for the management of restless leg syndrome.
    Toro BE
    J Neurosci Nurs; 2014 Aug; 46(4):227-32. PubMed ID: 24992148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.